Search
Now showing items 1-2 of 2
Cpt1c downregulation causes plasma membrane remodelling and anthracycline resistance in breast cancer
(MDPI, 2023)
Breast cancer (BC) is the most common malignancy in women worldwide. While the main systemic treatment option is anthracycline-containing chemotherapy, chemoresistance continues to be an obstacle to ...
To be or not to be a fat burner, that is the question for cpt1c in cancer cells
(Springer Nature, 2023)
There is an urgent need to identify reliable genetic biomarkers for accurate diagnosis, prognosis, and treatment of different tumor types. Described as a prognostic marker for many tumors is the neuronal ...